Navigation Links
Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
Date:11/28/2007

Company Plans to Initiate Phase III Program in First Half of 2008

LEXINGTON, Mass., Nov. 28 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced positive results from its Phase II octreotide implant trial in patients with acromegaly, a disorder characterized by excessive blood levels of growth hormone (GH) and insulin- like growth factor 1 (IGF-1). The implant utilizes the Company's patented Hydron technology to deliver effective levels of octreotide for six months. Octreotide is a synthetic peptide that mimics the natural hormone somatostatin to block release of GH. In the recently completed six-month trial, the octreotide implant effectively suppressed levels of GH and IGF-1 at rates similar to those seen with current FDA approved injectable formulations of octreotide. In addition, the drug was well tolerated.

"I am extremely pleased to report the successful completion of our octreotide implant trial and we are looking forward to the initiation of our Phase III program in the first half of 2008," stated Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "The market opportunity for a six-month octreotide implant for the treatment of acromegaly is substantial. The results of the trial demonstrate the potential of our octreotide implant, the only once every six month treatment, to improve the treatment options for people who suffer from this life-long debilitating condition. In addition, based on the successful results of this trial, we are exploring opportunities to expand our octreotide development program to address other indications where injectable formulations of octreotide are currently utilized, including carcinoid tumors."

The trial w
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Submission of New Drug Application
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... The global Bioinformatics ... sectors, products & services and application. And the rising ... increasing demand of advanced drugs for the diagnosis ... growth for bioinformatics market. The implementation of information ... as bioinformatics. Decreasing cost of DNA sequencing, continuous ...
(Date:9/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r8v22b/regulatory ) has announced the ... (London, UK - September 24-25, 2015)" conference to ... provides an introduction to Pharmaceutical Regulatory Affairs and the ... for those working in a support staff role. ... regulatory procedures required to register products in ...
(Date:9/1/2015)... , September 1, 2015 - ... GARFIELD-AF R egistry data presented at ... on the evolution of manag ... -   The first-ever two-year outcomes from ... ESC Congress 2015 expose that all-cause death was the most frequent major event ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
(Date:9/1/2015)... Los Angeles, CA (PRWEB) , ... September 01, 2015 , ... ... the American Medical Association, individuals with type 2 diabetes that participated in a three ... of diabetes three years down the line if they elected weight loss surgery at ...
(Date:9/1/2015)... , ... September 01, 2015 , ... From Aug. 17-21, ... and teenagers, from ages 6-18. Calvary’s Camp Compass® has taken place at Kingsborough Community ... 65 adult counselors, some of whom work for Calvary, and two junior counselors who ...
(Date:9/1/2015)... ... September 01, 2015 , ... Consumers overwhelmingly prefer to ... Dermatologic Surgery, according to a new survey that also offers insight on why ... Procedures – which reflects views on cosmetic medical treatments and ratings for 10 ...
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in ... MonaLisa Touch® , an innovative vaginal health laser procedure that prevents and resolves ... treatment for atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful ...
(Date:9/1/2015)... NC (PRWEB) , ... September 01, 2015 , ... With ... Technology, Engineering and Math) disciplines since its inception more than 35 years ago. A ... high-school students and their teachers - and, not just those intent on pursuing careers ...
Breaking Medicine News(10 mins):Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2
... poor supervisors to higher odds for heart attack , FRIDAY, Nov. ... is ruining your workday, you may be taking that stress to ... a higher risk of heart attack, and that,s not all: people ... The findings, which come from surveys of thousands of employees in ...
... year,s 23rd annual Great Chefs of Los Angeles (GCLA) ... a bounty of great-tasting organic snacks and beverages, all ... manufacturer of organic earth-friendly, extraordinary products that help preserve ... its premium, organic coffees, handpicked fair-trade mate teas, 100% ...
... accounts for better motor skills later, study suggests, , ... deprived of oxygen at birth often go on to ... infants can help prevent problems. , Now, a new ... of brain lesions in the babies. , Oxygen ...
... Nov. 6 Lippincott Williams & Wilkins is proud ... Professionals Need to Know About Sexual and Gender Diversity, ... DNSc, RN, Jeanne DeJoseph, CNM, PhD, and Peggy Chinn, ... www.NursingCenter.com/lgbtq and addresses health care disparities among the gay, ...
... ... recently released World Alzheimer Report declares that more than 35 million people worldwide will ... 16 independent living and assisted living, and Alzheimer,s/memory care communities in Wisconsin and Illinois, ... disease. , ...
... Nov. 5 The following was released today by Randall Terry: ... inside or outside in the hall at Nancy Pelosi,s office, #235 ... of the bill - all 2,000 pages (4,000) - and proceeded ... the floor. , Approximately 150 supporters were in the hall, chanting: ...
Cached Medicine News:Health News:Can a Bad Boss Make You Sick? 2Health News:Explorer's Bounty Contributing Charitable Bounty to Great Chefs of Los Angeles Event 2Health News:New E-Book Addresses LGBTQ Issues in the Education of Healthcare Professionals 2Health News:New E-Book Addresses LGBTQ Issues in the Education of Healthcare Professionals 3Health News:Top 10 Ways to Prevent or Delay Alzheimer's 2
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: